You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
羅欣藥業(002793.SZ):3項產品參與全國藥品集中採購中標
格隆匯 07-18 18:47

格隆匯7月18日丨羅欣藥業(002793.SZ)公佈,近日,國家組織藥品聯合採購辦公室發佈《關於公佈全國藥品集中採購(GY-YD2022-1)中選結果的通知》,公司下屬子公司山東羅欣投標的依達拉奉注射液、注射用頭孢美唑鈉及注射用美羅培南3個產品中標。中標產品基本情況如下:

依達拉奉注射液,用於改善急性腦梗死所致的神經症狀、日常生活活動能力和功能障礙。抑制肌萎縮側索硬化(ALS)所致功能障礙的進展。

注射用頭孢美唑鈉,本品適用於治療由對頭孢美唑鈉敏感的金黃色葡萄球菌、大腸埃希菌、肺炎桿菌、變形桿菌屬、摩氏摩根菌、普羅威登斯菌屬、消化鏈球菌屬、擬桿菌屬、普雷沃菌屬(雙路普雷沃菌除外)所引起的下述感染:1、敗血症;2、急性支氣管炎、肺炎、肺膿腫、膿胸、慢性呼吸道疾病繼發感染;3、膀胱炎、腎盂腎炎;4、腹膜炎;5、膽囊炎、膽管炎;6、前庭大腺炎、子宮內感染、子宮附件炎、子宮旁組織炎;7、頜骨周圍蜂窩織炎、頜炎。

注射用美羅培南,適用於成人和兒童由單一或多種對美羅培南敏感的細菌引起的感染:肺炎(包括院內獲得性肺炎)、尿路感染、腹腔內感染、婦科感染(如子宮內膜炎和盆腔炎)、皮膚軟組織感染、腦膜炎、敗血症。經驗性治療,對成人粒細胞減少症伴發熱患者,可單獨應用本品或聯合抗病毒藥或抗真菌藥使用。美羅培南單用或與其它抗微生物製劑聯合使用可用於治療多重感染。對於中性粒細胞減少或原發性、繼發性免疫缺陷的嬰兒患者,目前尚無本品的使用經驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account